Overcoming the Challenges of Allogeneic PBMC Isolation in GMP Manufacturing Workflow

Manufacturing failures in cell and gene therapy (CGT) carry high costs and risks, jeopardizing the timely production and delivery of safe, effective, and scalable allogeneic therapies. In this LinkedIn Live event, Dr. Yuki Kato Maves will present a real-world case study highlighting how Discovery Life Sciences partnered with a CGT developer to optimize the isolation workflow of GMP cryopreserved peripheral blood mononuclear cells (PBMCs). This initiative significantly reduces the risk of failure and CDMO costs, showcasing the transformative impact of streamlined processes on CGT production success. 

 

Speaker Information: 

Yuki Kato Maves, Ph.D.
Director, Product Management, Discovery Life Sciences
Dr. Yuki Kato Maves leads product management for Discovery Life Sciences, overseeing biospecimen products and services, including healthy donor starting cellular materials for cell and gene therapies. Dr. Kato Maves previously held key technical and commercial leadership roles at Crown Bioscience, where she spearheaded the growth of the company’s immuno-oncology and biomarker business. She earned her Ph.D. from UCLA, focusing on groundbreaking therapies that integrate RRV gene therapy and adoptive cell therapy for glioblastoma (GBM).